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ABSTRACT
Objective. Temporal lobe tumours, especially low-grade gliomas and glioneuronal tumours, are common causes of seizures in 
patients referred for epilepsy surgery. We here present our experience of surgical treatment of patients with intractable chronic 
epilepsy associated with temporal lobe tumours, focusing on the long-term surgical outcomes and the features associated with 
better seizure control.
Methods. In this study, we retrospectively analysed 44 consecutive patients from a total of 182 with refractory temporal lobe 
epilepsy presenting with long-term intractable epilepsy due to a temporal lobe tumour who were surgically treated at our 
institution between 2005 and 2015 with post-surgical follow-up of at least two years. All patients underwent a standard pre-
surgical evaluation that included: history and physical examination with a description of the seizure semiology, serial scalp EEG 
recording, brain MR imaging, and a detailed neuropsychological evaluation. Our surgical strategy comprised tumour resection, 
and combined mesial temporal and neocortical resection in most cases.
Results. No patient died during surgery or the postoperative course. Seven patients had postoperative complications, of whom two 
had permanent hemiparesis due to ischaemic stroke. At the final follow-up, a favourable seizure outcome (Engel Class I) was found in 
37 patients (84%), including 31 (70.5%) in Engel Class IA (excellent result). Two (4.5%) patients presented with an Engel Class II outcome 
(unfavourable outcome). Five patients (11.5%) were in Engel Classes III or IV (surgical failure). We found that complete resection of 
the hippocampus along with tumour and temporal pole removal was strongly associated with seizure freedom (p = 0.015). Patho-
logical diagnosis was also a significant prognostic indicator of tumour-related seizure freedom. Patients with a diagnosis of a glio-
neuronal tumour benefited from more seizure freedom after resection compared to those who had a low-grade glioma (p = 0.024).
Conclusion. The most appropriate management of tumour-related chronic temporal lobe epilepsy in adults appears to be tai-
lored temporal lobe resection including tumour and hippocampal complex removal. Surgical treatment of tumoural temporal 
lobe epilepsy demonstrates excellent results in terms of seizure improvement, especially in patients with glioneuronal tumours.
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Introduction
Seizures are a common manifestation of brain tumours. 
Tumour-related epilepsy significantly affects quality of life, 
and can result in significant morbidity [1–3]. Supratentorial 
tumours constitute 10–50% of the pathological diagnosis in 
patients undergoing surgery for chronic epilepsy [3, 4]. Among 
these, temporal lobe tumours, especially low-grade gliomas 
and glioneuronal tumours, are the most common causes of 
seizures in patients referred for epilepsy surgery [4]. In par-
ticular, glioneuronal tumours, low-grade brain tumours of 
glioneuronal origin that are often associated with focal cortical 
dysplasia (FCD), are commonly present with intractable epi-
lepsy. Epilepsy associated with low-grade temporal lobe brain 
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tumours is generally poorly controlled by antiepileptic drugs, 
although it is extremely responsive to surgical treatment. 
Low-grade tumours associated with refractory epilepsy are 
generally indolent entities in which there are both oncologi-
cal and epileptic aspects of neurosurgical treatment. Given 
the expected long-term survival of patients with low-grade 
tumours, achieving seizure control remains one of the most 
important treatment goals. 
Factors associated with seizure control remain incom-
pletely understood, and the best management strategy of 
tumour-related focal epilepsies has not been fully established. 
Some investigators have considered resection of the tumour 
alone to be sufficient for good seizure control [4–6], while 
others have advocated additional resection of epileptogenic 
zones adjacent to the tumour (usually the amygdala and hip-
pocampus) to optimise seizure outcome [7–12]. 
We present our experience of surgical treatment of patients 
with intractable chronic epilepsy associated with temporal lobe 
tumours, focusing on the long-term seizure outcomes and the 
features associated with better seizure control.
Material and methods
Patient population
A total of 182 patients with intractable temporal lobe epi-
lepsy (TLE) were surgically treated at our institution between 
2005 and 2015. A retrospective review of this group identified 
44 patients who presented with long-term intractable epilepsy 
due to a temporal lobe tumour who underwent temporal lobe 
resections with a postsurgical follow-up of at least two years. 
Two patients had been previously operated on at the referring 
institution with unsatisfactory results. The cohort comprised 
24 men and 20 women. The age at seizure onset ranged from 
2 to 40 years (mean 15.7 years). The mean age at the time of 
surgery was 30.9 years (range 18–56 years). The mean duration 
of epilepsy was 16 years (range 2–34 years). 
Preoperative evaluation
All patients underwent a standard presurgical evaluation 
that included: history and physical examination with a descrip-
tion of the seizure semiology, serial scalp EEG recording, brain 
MR imaging at 1.5 T, and a detailed neuropsychological evalua-
tion. In addition, most patients also underwent Wada testing to 
evaluate for memory and language asymmetry and video-EEG 
to confirm the localisation and semiology of the seizure. In 
some patients, a PET study was performed. Invasive subdural 
monitoring was never used. Cognitive function was tested to 
measure intellectual quotient and to assess memory, emotional 
processing, language, and executive function (Wechsler Adult 
Intelligence Scale-Revised, California Verbal Learning Test, 
Color Trails Test, Rey-Osterrieth Complex Figure, Tower of 
London, Boston Naming Test, Verbal Fluency Test). Health-
related quality of life (HRQoL) was evaluated by completing 
the QOLIE-31 instrument. 
The most common first seizure type was focal impaired 
awareness (61.3%). Focal to bilateral tonic-clonic seizures 
ware noted in 14 cases (41.2%). Seizures exceeded one per 
week in 12 patients (27.3%). Preoperative MR imaging showed 
typical tumour appearance in all but two cases, in whom the 
presence of FCD was suspected. Evidence for concomitant 
mesial temporal sclerosis was not observed, and cortical 
dysplasia adjacent to the glioneuronal tumours was suspected 
in five cases. 24 tumours were mesial and 20 were lateral. In 
21 patients (47.7%), the lesion was on the right side, and in 
the other 23 patients (52.3%) it was on the left side. Scalp EEG 
recordings demonstrated interictal spikes in the ipsilateral 
temporal lobe in 42 (95.5%) (eight patients with ipsilateral 
propagation, 10 patients with bilateral propagation, no propa-
gation in 24 patients), and bilateral interictal spikes in the other 
two (4.5%). A minimum of two pre-operative seizures were 
recorded during video EEG recordings in 38 (86.4%) patients 
(in the other six patients with typical seizure history and 
characteristic temporal lobe tumour appearance on MRI, pre-
operative seizure recordings were considered unnecessary). In 
this group, ictal onset recordings demonstrated a theta rhythm 
in 24 (63.2%) patients, a delta rhythm in 10 (26.3%), and sharp 
spikes in four (10.5%). 32 patients underwent a Wada test. In 
12 cases of mesial tumour location within the hippocampal 
complex, a Wada test was not performed. 15 (46.9%) patients 
had memory asymmetry on Wada testing compatible with me-
sial temporal lobe dysfunction. FDG-PET scan was performed 
in 12 (27.3%) patients and was positive in 11. 
All the clinical data for each patient was then reviewed by 
a multidisciplinary team (neurosurgeon, epilepsy neurologist, 
neuroradiologist, and neuropsychologist), and, if appropriate, 
patients were recommended for surgical therapy.
Surgical procedure
Total tumour resection along with epileptogenic zone 
removal were the primary goals of the operation so as to have 
a better seizure outcome and decrease the chances of recur-
rence and tumour upgrade. Our surgical strategy comprised 
tumour resection, and combined mesial temporal and neo-
cortical resection, with varying extents of resection between 
the two, depending on neuropsychological data, Wada testing, 
preoperative neurophysiology and intraoperative ECoG test-
ing, and the location of the tumour. Extended lesionectomy 
with sparing of mesial structures was rarely performed if 
preoperative Wada testing indicated a possibility of severe 
memory problems due to contralateral hippocampus memory 
insufficiency, or if the duration of epilepsy did not exceed five 
years, or if the tumour was located at the lateral temporal lobe. 
After initial electrocorticography (ECoG), tumours located 
in the lateral temporal lobe and the temporal neocortex were 
removed first, followed by resection of the deep structures. 
When located in the mesiotemporal region, tumours were 
accessed through a  transcortical approach with temporal 
pole resection and further resection of the tumour along the 
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amygdala and approximately 3 cm of the hippocampus. In 
most cases, a  trans-superior temporal gyrus approach was 
performed, limiting temporal pole resection, with most of the 
superior temporal gyrus spared. In some cases of left-sided 
tumour, the superior temporal gyrus was preserved. In general, 
our temporal lobe resection included the anterior 3.5 cm of the 
temporal neocortex in the dominant hemisphere. The anterior 
lateral temporal neocortex was not removed in a small group 
of patients in whom mesiotemporal tumour involvement and 
electro-clinical data indicated a strictly mesial origin of the 
epileptogenic zone. 
Incidental epileptic activity noted on ECoG after tempo-
ral lobe resection, evaluated as a result of surgical irritation, 
was usually not addressed with enhanced surgical resection. 
However, persistent spiking that produced a broadly spread-
ing field was addressed with further resection in some cases. 
Neuronavigation technique was not routinely used in temporal 
lobe epilepsy surgery. 
Pathological examination, follow up, and 
statistical analysis
All cases were histologically classified according to the 
CNS [13] and criteria for FCD diagnoses [14, 15]. Surgical and 
seizure outcomes were assessed in the outpatient epilepsy clinic 
at six, 12 and 24 months. Postoperative seizure outcome was 
graded according to the modified Engel classification, as set 
out in Table 1 [16]. An Engel Class I seizure control outcome 
was considered to be successful treatment, of which the most 
satisfactory of all was an Engel Class IA outcome. Engel Class 
II was considered to be an unsatisfactory outcome, while 
surgical failures were defined as Engel Classes III or IV. Neu-
rological and non-neurological complications were recorded. 
Antiepileptic medications were managed at the discretion of 
the treating epileptologist. In order to rule out the presence of 
any surgical complications in the early postoperative period 
(up to seven days after surgery), CT scanning with contrast 
enhancement (with 1.25 mm of separation acquisition) was 
routinely carried out. The completeness of tumour resection 
and the extent of temporal lobe resection were assessed inde-
pendently by the treating neurosurgeon and neuroradiologist 
in MR imaging performed in all patients 3-6 months after 
surgery. Volumetric MRI for quantitative assessment of the 
completeness of the tumour resection was performed in only 
a few cases.
The postoperative follow-up period ranged from 2-11 years 
(mean 5.3 years). HRQoL (QOLIE-31 test) was measured at 
the two-year follow-up.
The statistical tests used were the Pearson’s chi square, 
paired t-test, Mann–Whitney U test (non-parametric data), 
and Student’s t test (parametric data) for univariate analysis. 
Univariate and multivariate logistic regression analyses were 
performed to determine the impact of the independent clinico-
-pathological variables on seizure freedom status. All statistical 




Complete tumour removal was performed in all patients. 
Seven patients underwent limited resection including tumo-
ur and peritumoural rim, combined with various degrees of 
lateral neocortical corticectomy, leaving the amygdala and 
hippocampus. The remaining 37 patients had complete tumour 
resection and temporal pole and lateral neocortex removal 
along with the hippocampus. Persistent temporal spiking noted 
on ECoG after resection was addressed with further resection 
in four patients, and in only one case was it still present. 
Pathological findings
The histological examination revealed that glioneuronal 
tumours (32 patients, 72.7%) were more common than low-
-grade gliomas (12 patients, 27.3%), as set out in Table 2. DNT 
(dysembryoplastic neuroepithelial tumour) was the most 
frequent diagnosis, found in 17 patients (38.6%). Interestin-
gly, two cases (4.5%) of anaplastic tumours had a seven-year 
history of intractable seizures. Concomitant ipsilateral mesial 
temporal sclerosis was noted in one patient (2.3%), indicative 
of dual pathology, even though there was no evidence for MTS 
on preoperative MRI. Furthermore, histological examination 
in 19 (43.2%) cases showed FCD, namely four cases of FCD 
Table 1. Engel Classification
Class I: Free of disabling seizures
IA: Completely seizure-free since surgery
IB: Non-disabling simple partial seizures only since surgery
IC: Some disabling seizures after surgery, but free of disabling seizures 
for at least two years
ID: Generalised convulsions with antiepileptic drug withdrawal only
Class II: Rare disabling seizures (almost seizure-free)
A: Initially free of disabling seizures, but rare seizures now
B: Rare disabling seizures since surgery
C: More than rare disabling seizures since surgery, but rare seizures for 
the last two years
D: Nocturnal seizures only
Class III: Worthwhile improvement
A: Worthwhile seizure reduction
B: Prolonged seizure-free intervals amounting to more than half of the 
follow-up period, but not < 2 years
Class IV: No worthwhile improvement
A: Significant seizure reduction
B: No appreciable change
C: Seizures worse
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Table 2. Pathological findings in 44 tumour epilepsy-related patients
Tumour type No. of patients (%)
DNT (WHO GI) 17 (38.6)
Ganglioglioma (WHO GI) 14 (31.8)
Ganglioglioma anaplasticum (WHO GIII) 1 (2.3)
Astrocytoma pilocyticum (WHO GI) 5 (11.4)
Oligodendroglioma (WHO GII) 2 (4.5)
Pleomorphic xanthoastrocytoma (WHO GII) 2 (4.5)
Astrocytoma fibryllare (WHO GII) 1 (2.3)
Atrocytoma anaplasticum (WHO GIII) 1 (2.3)
Angiocentric glioma (WHO GI) 1 (2.3)
Type IIA and 15 cases of FCD Type IIIB. All but one FCDs 
were associated with glioneuronal tumours. 
Surgical outcome and complications
No patient died during surgery or the postoperative co-
urse. Seven (13.6%) patients had postoperative neurological 
complications. Two (4.5%) of them had permanent hemipa-
resis due to ischaemic stroke (in one case hemiparesis was 
accompanied by dysphasia and 3rd cranial nerve deficit). In 
the other five patients, transient postoperative complications 
were noted and included: temporary dysphasia in two patients, 
transitory hemiparesis in one, postoperative haematoma in 
one, and intracranial hypotension syndrome (hypoperfusion 
syndrome) in one. In eight (18.2%) patients, significant new 
field cuts (hemianopsia) were observed.  
MRI showed evidence of tumour recurrence in the patient 
with anaplastic ganglioglioma (GG). This patient was treated 
oncologically and died six years after surgery. The other patient 
with anaplastic astrocytoma, after postoperative radiotherapy 
underwent a  second craniotomy because of radiographic 
suspicion of tumour recurrence. However, no tumour was 
identified on pathology, which showed only the presence of 
radiation necrosis.
Seizure outcome
At the final follow-up, favourable seizure outcome (Engel I) 
was found in 37 patients (84%), including 31 (70.5%) in Engel 
Class IA (excellent result). Two (4.5%) patients presented with 
an Engel Class II outcome (unfavourable outcome). Five pa-
tients (11.5%) were in Engel Classes III or IV (surgical failure). 
Statistical comparisons of the various clinical, radiological, 
perioperative, and pathological factors in patients with an Engel 
Class I outcome and patients with Engel Classes II-IV outcomes 
are set out in Table 3, and prognostic indicators are identified. 
Four parameters correlated with the rate of seizure freedom 
after surgery: extent of temporal lobe resection (p = 0.001), 
postoperative ECoG findings (p = 0.022), and pathological diag-
nosis and tumour-associated FCD occurrence (p = 0.004 and 
p = 0.012, respectively). Of the seven patients who underwent 
lesionectomy, three were in Engel Class I (42.9%), one was in 
Engel Class II, and three were in Engel Classes III–IV. Among 
individuals who had complete resection of the hippocampus 
along with tumour and extended temporal pole removal, the po-
stoperative seizure freedom rate was 91.9% (34 were Engel Class 
I, one was Engel Class II, and two were Engel Classes III–IV). 
Pathological diagnosis was also a significant prognostic 
indicator of seizure freedom. Patients with a diagnosis of 
a glioneuronal tumour benefited from a 93.8% rate of seizure 
freedom after resection, compared to only 58.3% of those who 
had a low-grade glioma. Moreover, tumour-associated FCDs 
significantly correlated with a satisfactory seizure outcome.
The use of intraoperative ECoG was found to influence the 
outcome. Of 30 patients who presented with no epileptogenic 
discharges after resection, Engel Class I outcome was obtained 
in 28 (93.3%). In contrast, Engel Class I was seen in 6/8 (75%) 
patients with sharp spikes occurring postoperatively. However, 
intraoperative ECoG was not used in six patients of whom only 
three (50%) were free of seizures after surgery.
Table 4 shows how logistic regression analyses were used 
for further scrutiny of the four variables found on chi-square 
testing to prognosticate significant factors for seizure outcome. 
We found that the extent of resection produced the biggest 
difference in postoperative seizure status: complete resection 
of the hippocampus along with tumour and extended temporal 
pole removal was strongly associated with seizure freedom (p 
= 0.015). This implies that resection sparing the hippocampal-
-parahippocampal complex could greatly increase the risk of 
persistent seizures. Furthermore, we found that pathological 
diagnosis independently predicted postoperative seizure 
status: glioneuronal tumours were associated with a better 
seizure outcome (p = 0.024). 
Quality of life outcome
There was a statistically significant improvement for the 
overall QOLIE-31 score (46.73 +/-21.16 before surgery and 
69.31 +/- 29.17 after surgery, p < 0.005). However, there was 
no statistically significant effect of epilepsy surgery on HRQoL 
changes between the various subgroups based on the Engel 
class surgical outcome.
Discussion
Chronic medically intractable epilepsy secondary to low-gra-
de temporal tumours is well known [17]. Advances in imaging 
and neuropathological techniques have allowed such tumours 
to be detected with increasing frequency before surgery [18]. 
In determining the most appropriate treatment for patients 
with tumoural epilepsy, it is important to understand the 
natural history of this disease and its treatment options and 
surgical outcomes. Usually epilepsy associated with low-grade 
tumours is insufficiently controlled by antiepileptic drugs, but 
is extremely responsive to surgical treatment.  
It should be emphasised that in most of these patients, 
epilepsy control is the main goal of surgery because most are 
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Figure 1. Preoperative coronal T1 (A) and coronal T2 (B) MR image demonstrating extensive DNT associated with FCD type IIA of the left 
temporal lobe (white arrows). Postoperative coronal Inversion Recovery (IR) (C) and coronal FLAIR (D) MR image obtained after temporal 
lobe resection including tumour, lateral neocortex and hippocampal complex removal
A B
C D
benign tumours of glioneuronal or glial origin [19]. However, 
in those with a diffuse low-grade glioma (WHO GII), the 
oncological aspects of treatment should prevail according to 
the progressive course of these tumours. 
In this report, we have presented our experience in 44 cases 
involving chronic intractable epilepsy associated with temporal 
lobe tumours, and we have discussed our management and 
outcomes.
Pathological diagnosis
It has been previously reported that glioneuronal tumo-
urs and low-grade gliomas account for the great majority of 
tumours in patients with chronic epilepsy [20]. These are 
generally benign and indolent tumours in which epilepsy 
is usually the main problem, although the rare occurrence 
of malignant evolution, as in two of our cases, has been 
reported.  
Among the published series, however, there is no consen-
sus regarding which histological entity is the most common. In 
our series, DNT was the most common diagnosis, consistent 
with other reports [21]. Other groups have reported ganglio-
glioma [22] and astrocytoma [3] to be the most common. 
Gangliogliomas and DNTs may have intrinsic epileptogenic 
properties due to their neuronal and glial components, and 
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Table 3. Comparison of demographic, clinical and pathological characteristics of patients with tumour-related temporal lobe epilepsy between those who 
are seizure-free and those with persistent seizures
Variables
Seizure free  
(n = 37) 
No. of patients (%)
Persistent seizures (n = 7)
No. of patients (%)
P value
Sex, male/female* 21 (56.8) / 16 (43.2) 3 (42.9) / 4 (57.1) 0.498
Initial precipitating injury, yes/no* 9 (24.3) / 28 (75.7) 2 (28.6) / 5 (71.4) 0.812
Type of first seizure, tonic-clonic / focal impaired awareness / 
focal aware*
11 (29.7) / 22 (59.5) / 4 (10.8) 2 (28.6) / 5 (71.4) / 0 (0) 0.639
Mean age at surgery (SD), years** 30.92 (+/- 8.496) 33.14 (+/- 11.992) 0.555
Mean age at seizure onset (SD), years** 15.97 (+/- 8.241) 13.71 (+/- 7.064) 0.502
Mean duration of epilepsy (SD), years** 14.73 (+/- 8.061) 18.29 (+/- 10.029) 0.309
Number of seizures per week (preop),  < 1 / > = 1* 26 (70.3) / 11 (29.7) 6 (85.7) / 1 (14.3) 0.400
Focal to bilateral tonic-clonic seizures, yes/no* 11 (29.7) / 26 (70.3) 3 (42.9) / 4 (57.1) 0.494
Propagation of focal changes on scalp EEG, yes/no* 15 (40.5) / 22 (59.5) 3 (42.9) /4 (57.1) 0.909
Ictal onset recordings on video-EEG, theta/delta/sharp spikes/
data lacking*
7 (18.9) / 22 (59.5) / 4 (10.8) / 
4 (10.8)
3 (42.9) / 2 (28.6) / 0 (0) / 2 (28.6) 0.201
Tumour location, mesial/lateral* 22 (59.5) / 15 (40.5) 2 (28.6) / 5 (71.4) 0.132
Side of surgery, right/left* 17 (45.7) / 20 (54.1) 4 (57.1) / 3 (42.9) 0.587
Extent of temporal lobe resection, lesionectomy/complete TLR* 3 (8.1) / 34 (91.9) 4 (57.1) / 3 (42.9) 0.001
Postoperative ECoG findings, sharp spikes/slow waves/data 
lacking*
6 (16.2) / 28 (75.7) / 3 (8.1) 2 (28.6) / 2 (28.6) / 3 (42.9) 0.022
Seizure in early post-op period, yes/no* 7 (18.9) / 30 (81.1) 1 (14) / 6 (85.7) 0.771
Post-op complications, yes/no* 10 (27) / 27 (73) 0 (0) / 7 (100) 0.118
Tumour pathology, glioneuronal/glial* 30 (81.1) / 7 (18.9) 2 (28.6) / 5 (71.4) 0.004
Tumour-associated FCD occurrence, yes/no* 19 (51.4) / 18 (48.6) 0 (0) / 7 (100) 0.012
*Pearson’s chi square test, ** t Student test, TLR — temporal lobe resection, FCD — focal cortical dysplasia
Table 4. Predictors of seizure class I outcome (logistic regression model)
Variables Wald Exp (B) (95% CI) P value
Extent of temporal lobe resection, lesionectomy/complete TLR 5.953 0.47 (0.004–0.547) 0.015
Postoperative ECoG findings, sharp spikes/slow waves/data lacking 1.134 2.733 (0.429–17.397) 0.287
Tumour pathology, glioneuronal/glial 5.061 14.867 (1.416–156.136) 0.024
Tumour-associated FCD occurrence, yes/no 2.355 0.136 (0.11–1.738) 0.125
the precise epileptological mechanisms associated with these 
lesions are still under investigation [7, 23–25]. 
Of importance is that our report confirms the high inci-
dence of tumour-associated cortical dysplasia (43.2%) and 
the presence of cases of mesial temporal sclerosis associated 
with neoplasm. 
The above observations have led us to adopt the strategy 
of extended temporal lobe resection in cases of tumoural 
drug-resistant epilepsy. Glioneuronal tumours are associated 
with FCD in 30–80% of cases [24–26], and have been consi-
dered by some authors as the extreme neoplastic end of the 
histopathological spectrum of cortical dysplasia [8, 15, 27]. 
The new ILAE classification system for FCDs introduced 
FCD type IIIB to encapsulate cases of FCD type I adjacent to 
a low-grade tumour associated with epilepsy [14]. However, 
the specific role of each of them in epileptogenesis is still not 
fully defined [8, 15, 27]. 
While rare, there have been reports of anaplastic transfor-
mation of gangliogliomas [28]. In our series, there were two 
cases of anaplastic tumours. Both of them had a seven-year 
history of intractable seizures, suggesting the possibility of 
anaplastic transformation. 
Surgical treatment and seizure outcome
Temporal lobe resection is the long-established safe and 
effective treatment for temporal lobe epilepsy [29]. In those 
patients who harbour temporal lobe tumours however, there 
has been considerable controversy regarding the most appro-
priate management, with some advocating lesionectomy only, 
and others arguing for more extensive resection [17, 20, 30]. 
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Figure 2. Preoperative coronal Inversion Recovery (IR) (A) and coronal FLAIR (B) MR image demonstrating ganglioglioma associated with 
FCD type IIIB of the right temporal lobe (white arrows). Postoperative coronal Inversion Recovery (IR) (C) and coronal FLAIR (D) MR image 
obtained after tailored temporal lobe resection including tumour, temporal pole and hippocampal complex removal
Because it is unclear how much the peritumoural tissue 
contributes to the initiation and propagation of seizures, the 
extent of resection that must be performed is not obvious [10]. 
The only consensus appears to be that gross-total resection, 
as long as it can be safely performed, should be the minimum 
goal of surgery [17, 31, 32]. It seems that temporal low-grade 
tumours, especially those of glioneuronal origin located in 
the mesiotemporal region, are a distinct clinico-pathological 
group with a more widespread epileptic network and complex 
epileptogenic mechanisms. Here, tailored resection appears to 
offer the best results for seizure outcome [26, 33–35]. Lesionec-
tomy is considered sufficient for an optimal seizure outcome 
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in temporolateral and extratemporal low-grade tumours [33]. 
In our series, our surgical strategy was independent of the 
histological type expected. The extent of resection was based 
on identification of the epileptogenic area and determined 
by noninvasive presurgical clinical and neurophysiological 
investigations.  
In addition to gross-total removal of the tumour, 84% of 
patients underwent resection of the amygdala and hippocam-
pus. We found that the extent of resection led to the biggest 
difference in postoperative seizure status. 
Resection of the hippocampal-parahippocampal complex 
in addition to the tumour, especially when it is not involved 
in the lesion and appears normal on MRI, is controversial. 
However, it is well known that the mesial temporal structures 
have a great epileptogenicity, and their resection is considered 
crucial for surgical success in refractory mesial temporal lobe 
epilepsy, because both the lesion and the hippocampus are 
epileptogenic. 
We found that our approach of extended temporal lobe 
resection provided for optimal resection of epileptogenic tissue 
by removing both mesial temporal structures and invisible 
foci of highly epileptogenic cortical dysplasia adjacent to the 
neoplasm. Although a clear relationship between epilepsy and 
tumour-associated FCD has not been fully established, it has 
been reported that such an association may determine a less 
effective control of seizures after simple lesionectomy [7, 8, 
24, 36]. Glioneuronal tumours are frequently embedded in 
dysplastic cortex, which is more likely to be removed when 
performing a tailored resection [26]. There is also no agre-
ement on the best time for surgery, as these tumours may not 
show significant growth for many years. 
The decision to proceed to surgery in our patients was ba-
sed on the fact that epilepsy associated with low-grade tumours 
is a typical example of surgically-remediable epilepsy with an 
excellent seizure outcome, and effective surgical treatment 
might avoid possible drug-induced adverse cognitive effects 
[7, 9, 11, 21, 26]. Moreover, epilepsy surgery may also prevent 
the possibility of malignant transformation [7, 9, 11, 12, 24]. 
The patients in our series experienced significantly impro-
ved outcomes with respect to seizure frequency. These results 
are in line with other similar series, in which more than 80% 
of patients were free of disabling seizures after surgery [3, 4, 
17, 22]. We found that low-grade tumour type (glioneuronal 
versus low-grade glioma) predicted seizure freedom after 
surgery. This might be explained by the fact that gross-total 
tumour resection is the strongest predictor for favourable 
seizure outcome [11, 34, 37–39]. However, it may prove diffi-
cult in cases of low-grade gliomas. WHO Grade II low-grade 
gliomas could present in locations that are challenging to 
access surgically and involve the paralimbic system. Further-
more, even after presumed total tumour resection, there are 
residual tumour cells acting as an epileptic focus, since it has 
been demonstrated that gliomas involve the brain beyond the 
signal abnormality visible on MRI [40]. 
In our series, there were no statistical differences between 
clinical factors consistent with epilepsy severity and seizure 
outcome. It has been reported that strong predictors of seizure 
freedom after surgery are short duration of epilepsy and lack 
of focal to bilateral seizures before surgery [34, 41].  Shorter 
epilepsy duration has been shown to predict improved seizure 
outcome in systematic reviews examining gangliogliomas 
and low-grade gliomas [37, 42]. However, in patients with 
temporal lobe epilepsy, epilepsy duration has not been found 
to be predictive of its severity [43]. The use of intraoperative 
ECoG has been reported not to be associated with improved 
seizure outcomes, which is consistent with our findings. But 
caution in interpreting this finding is advised, because ECoG 
may only be used in more severe cases [34].
The rates of permanent new neurological deficits in other 
series are comparable to ours [44]. Temporal lobe lesions carry 
a particular risk for the visual pathways, although postope-
rative quadrantanopia is considered not to be a significant 
complication, instead being seen as a non-disturbing accep-
table side effect [45]. 
Outcome measures have been focused mainly on seizure 
relief, but it is also necessary to look at outcomes related to psy-
chosocial functioning and health-related quality of life (HRQoL) 
[46]. Postoperative improvement in psychosocial functioning 
has been shown, although the small number of subjects in Engel 
Class I, and Engel Classes II-IV surgical outcomes, limited the 
power to detect a difference between the subgroups.
Conclusions
The most appropriate management of tumour-related 
chronic temporal lobe epilepsy in adults appears to be tailored 
temporal lobe resection including tumour and hippocampal 
complex removal. Surgical treatment of tumoural temporal 
lobe epilepsy demonstrates excellent results with seizure im-
provement, especially in patients with glioneuronal tumours.
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